Xing Deng
YOU?
Author Swipe
View article: A preliminary study of C-arm CT-assisted Adrenal Vein Sampling in Primary Aldosteronism
A preliminary study of C-arm CT-assisted Adrenal Vein Sampling in Primary Aldosteronism Open
Aim Evaluate the success rate and accuracy of C-arm CT technology in adrenal venous sampling, and analyze the impact of C-arm CT technology on patient radiation dose. Methods The researchers collected demographic data, adrenal venous sampl…
View article: HDAug: Optimizing Medical Image Segmentation through Hyperparameter-Driven Brightness and Contrast Augmentation for Deep Learning Models
HDAug: Optimizing Medical Image Segmentation through Hyperparameter-Driven Brightness and Contrast Augmentation for Deep Learning Models Open
Traditional data augmentation methods, which employ static hyperparameters, often lead to model overfitting. To address this limitation, a novel hyperparameter-driven data augmentation approach (HDAug) is introduced in this study. Training…
View article: Deep Learning Applications in Chemical Instrument Recognition: A Review
Deep Learning Applications in Chemical Instrument Recognition: A Review Open
View article: Research on the influence of environment temperature and running condition on the driving range of battery electric vehicle
Research on the influence of environment temperature and running condition on the driving range of battery electric vehicle Open
Reduction of the driving range under either cold temperature or real-world running condition has become the biggest challenge for battery electric vehicle (BEV). In this paper, a simulation platform that combines a kinematics model, a ther…
View article: Association between increased BMI and cognitive function in first-episode drug-naïve male schizophrenia
Association between increased BMI and cognitive function in first-episode drug-naïve male schizophrenia Open
Objective Although the adverse effects of obesity in schizophrenia are documented, there is limited research exists on the implications for untreated initial schizophrenia. Our investigation aimed to explore the connections between BMI and…
View article: Highly Differentiated Target Detection under Extremely Low-Light Conditions Based on Improved YOLOX Model
Highly Differentiated Target Detection under Extremely Low-Light Conditions Based on Improved YOLOX Model Open
This paper expounds upon a novel target detection methodology distinguished by its elevated discriminatory efficacy, specifically tailored for environments characterized by markedly low luminance levels.Conventional methodologies struggle …
View article: An Investigation of Frequency-Domain Pruning Algorithms for Accelerating Human Activity Recognition Tasks Based on Sensor Data
An Investigation of Frequency-Domain Pruning Algorithms for Accelerating Human Activity Recognition Tasks Based on Sensor Data Open
View article: Comprehensive Survey of the Landscape of Digital Twin Technologies and Their Diverse Applications
Comprehensive Survey of the Landscape of Digital Twin Technologies and Their Diverse Applications Open
The concept of the digital twin, also known colloquially as the DT, is a fundamental principle within Industry 4.0 framework. In recent years, the concept of digital siblings has generated considerable academic and practical interest. Howe…
View article: Figure S3 from Purinostat Mesylate Is a Uniquely Potent and Selective Inhibitor of HDACs for the Treatment of <i>BCR-ABL</i>–Induced B-Cell Acute Lymphoblastic Leukemia
Figure S3 from Purinostat Mesylate Is a Uniquely Potent and Selective Inhibitor of HDACs for the Treatment of <i>BCR-ABL</i>–Induced B-Cell Acute Lymphoblastic Leukemia Open
Toxicity studies of PM.
View article: Data from Purinostat Mesylate Is a Uniquely Potent and Selective Inhibitor of HDACs for the Treatment of <i>BCR-ABL</i>–Induced B-Cell Acute Lymphoblastic Leukemia
Data from Purinostat Mesylate Is a Uniquely Potent and Selective Inhibitor of HDACs for the Treatment of <i>BCR-ABL</i>–Induced B-Cell Acute Lymphoblastic Leukemia Open
Purpose:This study was to perform preclinical evaluation of a novel class I and IIb HDAC-selective inhibitor, purinostat mesylate, for the treatment of Ph+ B-cell acute lymphoblastic leukemia (B-ALL).Experimental Design:Biochemi…
View article: Figure S1 from Purinostat Mesylate Is a Uniquely Potent and Selective Inhibitor of HDACs for the Treatment of <i>BCR-ABL</i>–Induced B-Cell Acute Lymphoblastic Leukemia
Figure S1 from Purinostat Mesylate Is a Uniquely Potent and Selective Inhibitor of HDACs for the Treatment of <i>BCR-ABL</i>–Induced B-Cell Acute Lymphoblastic Leukemia Open
Baseline leukemia burden of the model mice before PM treatment and western blot analysis the levels of Ac-H3, Ac-H4 in bone marrow cells after PM treatment.
View article: Data from Purinostat Mesylate Is a Uniquely Potent and Selective Inhibitor of HDACs for the Treatment of <i>BCR-ABL</i>–Induced B-Cell Acute Lymphoblastic Leukemia
Data from Purinostat Mesylate Is a Uniquely Potent and Selective Inhibitor of HDACs for the Treatment of <i>BCR-ABL</i>–Induced B-Cell Acute Lymphoblastic Leukemia Open
Purpose:This study was to perform preclinical evaluation of a novel class I and IIb HDAC-selective inhibitor, purinostat mesylate, for the treatment of Ph+ B-cell acute lymphoblastic leukemia (B-ALL).Experimental Design:Biochemi…
View article: Figure S2 from Purinostat Mesylate Is a Uniquely Potent and Selective Inhibitor of HDACs for the Treatment of <i>BCR-ABL</i>–Induced B-Cell Acute Lymphoblastic Leukemia
Figure S2 from Purinostat Mesylate Is a Uniquely Potent and Selective Inhibitor of HDACs for the Treatment of <i>BCR-ABL</i>–Induced B-Cell Acute Lymphoblastic Leukemia Open
PM showed anti-leukemia effects in Ph+ T315I mutation and Ph+ wild type B-ALL mouse models, and the clinical information of primary cells of Ph+ B-ALL patient samples.
View article: Supplemental Information from Purinostat Mesylate Is a Uniquely Potent and Selective Inhibitor of HDACs for the Treatment of <i>BCR-ABL</i>–Induced B-Cell Acute Lymphoblastic Leukemia
Supplemental Information from Purinostat Mesylate Is a Uniquely Potent and Selective Inhibitor of HDACs for the Treatment of <i>BCR-ABL</i>–Induced B-Cell Acute Lymphoblastic Leukemia Open
Supplementary Methods and Supplementary Figure Legends
View article: Figure S2 from Purinostat Mesylate Is a Uniquely Potent and Selective Inhibitor of HDACs for the Treatment of <i>BCR-ABL</i>–Induced B-Cell Acute Lymphoblastic Leukemia
Figure S2 from Purinostat Mesylate Is a Uniquely Potent and Selective Inhibitor of HDACs for the Treatment of <i>BCR-ABL</i>–Induced B-Cell Acute Lymphoblastic Leukemia Open
PM showed anti-leukemia effects in Ph+ T315I mutation and Ph+ wild type B-ALL mouse models, and the clinical information of primary cells of Ph+ B-ALL patient samples.
View article: Figure S1 from Purinostat Mesylate Is a Uniquely Potent and Selective Inhibitor of HDACs for the Treatment of <i>BCR-ABL</i>–Induced B-Cell Acute Lymphoblastic Leukemia
Figure S1 from Purinostat Mesylate Is a Uniquely Potent and Selective Inhibitor of HDACs for the Treatment of <i>BCR-ABL</i>–Induced B-Cell Acute Lymphoblastic Leukemia Open
Baseline leukemia burden of the model mice before PM treatment and western blot analysis the levels of Ac-H3, Ac-H4 in bone marrow cells after PM treatment.
View article: Table S4 from Purinostat Mesylate Is a Uniquely Potent and Selective Inhibitor of HDACs for the Treatment of <i>BCR-ABL</i>–Induced B-Cell Acute Lymphoblastic Leukemia
Table S4 from Purinostat Mesylate Is a Uniquely Potent and Selective Inhibitor of HDACs for the Treatment of <i>BCR-ABL</i>–Induced B-Cell Acute Lymphoblastic Leukemia Open
4-week toxicity studies of PM on SD rats and beagle dogs.
View article: Table S3 from Purinostat Mesylate Is a Uniquely Potent and Selective Inhibitor of HDACs for the Treatment of <i>BCR-ABL</i>–Induced B-Cell Acute Lymphoblastic Leukemia
Table S3 from Purinostat Mesylate Is a Uniquely Potent and Selective Inhibitor of HDACs for the Treatment of <i>BCR-ABL</i>–Induced B-Cell Acute Lymphoblastic Leukemia Open
PM concentration in tissues after a single intravenous administration to BL-2 bearing mice (Mean {plus minus} SD; n = 4).
View article: Table S3 from Purinostat Mesylate Is a Uniquely Potent and Selective Inhibitor of HDACs for the Treatment of <i>BCR-ABL</i>–Induced B-Cell Acute Lymphoblastic Leukemia
Table S3 from Purinostat Mesylate Is a Uniquely Potent and Selective Inhibitor of HDACs for the Treatment of <i>BCR-ABL</i>–Induced B-Cell Acute Lymphoblastic Leukemia Open
PM concentration in tissues after a single intravenous administration to BL-2 bearing mice (Mean {plus minus} SD; n = 4).
View article: Table S2 from Purinostat Mesylate Is a Uniquely Potent and Selective Inhibitor of HDACs for the Treatment of <i>BCR-ABL</i>–Induced B-Cell Acute Lymphoblastic Leukemia
Table S2 from Purinostat Mesylate Is a Uniquely Potent and Selective Inhibitor of HDACs for the Treatment of <i>BCR-ABL</i>–Induced B-Cell Acute Lymphoblastic Leukemia Open
IC50 values of PM and LBH589 against various hematological tumor cell lines.
View article: Table S1 from Purinostat Mesylate Is a Uniquely Potent and Selective Inhibitor of HDACs for the Treatment of <i>BCR-ABL</i>–Induced B-Cell Acute Lymphoblastic Leukemia
Table S1 from Purinostat Mesylate Is a Uniquely Potent and Selective Inhibitor of HDACs for the Treatment of <i>BCR-ABL</i>–Induced B-Cell Acute Lymphoblastic Leukemia Open
In vitro activity of PM on histone deacetylase and kinases.
View article: Table S4 from Purinostat Mesylate Is a Uniquely Potent and Selective Inhibitor of HDACs for the Treatment of <i>BCR-ABL</i>–Induced B-Cell Acute Lymphoblastic Leukemia
Table S4 from Purinostat Mesylate Is a Uniquely Potent and Selective Inhibitor of HDACs for the Treatment of <i>BCR-ABL</i>–Induced B-Cell Acute Lymphoblastic Leukemia Open
4-week toxicity studies of PM on SD rats and beagle dogs.
View article: Supplemental Information from Purinostat Mesylate Is a Uniquely Potent and Selective Inhibitor of HDACs for the Treatment of <i>BCR-ABL</i>–Induced B-Cell Acute Lymphoblastic Leukemia
Supplemental Information from Purinostat Mesylate Is a Uniquely Potent and Selective Inhibitor of HDACs for the Treatment of <i>BCR-ABL</i>–Induced B-Cell Acute Lymphoblastic Leukemia Open
Supplementary Methods and Supplementary Figure Legends
View article: Table S1 from Purinostat Mesylate Is a Uniquely Potent and Selective Inhibitor of HDACs for the Treatment of <i>BCR-ABL</i>–Induced B-Cell Acute Lymphoblastic Leukemia
Table S1 from Purinostat Mesylate Is a Uniquely Potent and Selective Inhibitor of HDACs for the Treatment of <i>BCR-ABL</i>–Induced B-Cell Acute Lymphoblastic Leukemia Open
In vitro activity of PM on histone deacetylase and kinases.
View article: Table S2 from Purinostat Mesylate Is a Uniquely Potent and Selective Inhibitor of HDACs for the Treatment of <i>BCR-ABL</i>–Induced B-Cell Acute Lymphoblastic Leukemia
Table S2 from Purinostat Mesylate Is a Uniquely Potent and Selective Inhibitor of HDACs for the Treatment of <i>BCR-ABL</i>–Induced B-Cell Acute Lymphoblastic Leukemia Open
IC50 values of PM and LBH589 against various hematological tumor cell lines.
View article: Figure S3 from Purinostat Mesylate Is a Uniquely Potent and Selective Inhibitor of HDACs for the Treatment of <i>BCR-ABL</i>–Induced B-Cell Acute Lymphoblastic Leukemia
Figure S3 from Purinostat Mesylate Is a Uniquely Potent and Selective Inhibitor of HDACs for the Treatment of <i>BCR-ABL</i>–Induced B-Cell Acute Lymphoblastic Leukemia Open
Toxicity studies of PM.
View article: Regional citrate anticoagulation for continuous renal replacement therapy in newborns
Regional citrate anticoagulation for continuous renal replacement therapy in newborns Open
Background Regional citrate anticoagulant (RCA) is recommended as the preferred anticoagulant regimen for continuous renal replacement therapy (CRRT) in adults; however, it is rarely reported in neonates due to concerns associated with the…
View article: MNIST Handwritten Digit Classification Based on Convolutional Neural Network with Hyperparameter Optimization
MNIST Handwritten Digit Classification Based on Convolutional Neural Network with Hyperparameter Optimization Open
Accurate handwriting recognition has been a challenging computer vision problem, because static feature analysis of the text pictures is often inadequate to account for high variance in handwriting styles across people and poor image quali…
View article: Determination of Five Isothiazolinone Preservatives in Liquid Detergents by High Performance Liquid Chromatography
Determination of Five Isothiazolinone Preservatives in Liquid Detergents by High Performance Liquid Chromatography Open
In this study, an associate analytical approach supported by high performance liquid chromatography (HPLC) was developed to analyze five isothiazolinones in liquid detergents in the meanwhile. The isothiazolinones were extracted from liqui…
View article: Giant superlinear power dependence of photocurrent based on layered Ta$_2$NiS$_5$ photodetector
Giant superlinear power dependence of photocurrent based on layered Ta$_2$NiS$_5$ photodetector Open
Photodetector based on two-dimensional (2D) materials is an ongoing quest in optoelectronics. These 2D photodetectors are generally efficient at low illuminating power but suffer severe recombination processes at high power, which results …